Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
Belimumab and anifrolumab show different strengths for lupus patients
This meta-analysis compared belimumab and anifrolumab using indirect evidence from randomized controlled trials involving 4332 patients with…
A new analysis compares two lupus drugs. Belimumab worked better for overall disease control, while anifrolumab helped lower steroid doses a…
Meta-analysis links CYP2C19*2 polymorphism to reduced cyclophosphamide toxicity in SLE
Genetic marker may lower risk of cyclophosphamide toxicity in lupus patients
This meta-analysis of 5 observational studies found that the CYP2C19*2 genetic polymorphism is associated with a protective effect against…
A genetic variant linked to lower risk of cyclophosphamide side effects in lupus patients, though evidence remains limited by small study si…
Systematic Review Links Lysosomal Pathways to Autoimmune Kidney Disease Progression
Lysosomal pathways may control autoimmune kidney disease progression
This systematic review synthesizes evidence that lysosomal functions act as checkpoints in autoimmune kidney diseases like lupus nephritis a…
New evidence suggests that targeting lysosomal functions could offer a new way to manage serious autoimmune kidney diseases.
Mini Review Covers Complement Pathways in Kidney Diseases and Injuries
Review offers overview of kidney disease treatments and risks
This mini review examines the role of complement-mediated mechanisms across multiple renal pathologies without specific outcome data.
This mini review summarizes current knowledge on kidney conditions like lupus nephritis and transplant care, offering a broad look at the fi…
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
LOC100130476 rs80213143 variant associated with SLE susceptibility and renal involvement in Chinese Han cohort
Genetic variant linked to lupus susceptibility and kidney involvement in Chinese study
A cohort study in a Chinese Han population found the rs80213143 variant at LOC100130476 was associated with systemic lupus erythematosus sus…
A specific genetic marker found in Chinese patients is strongly linked to lupus and predicts more severe kidney disease.
Review examines glucose metabolic reprogramming in SLE and lupus nephritis pathogenesis
Review explores how sugar metabolism changes might fuel lupus immune system problems
A systematic review synthesizes evidence on glucose metabolic reprogramming in immune cells in systemic lupus erythematosus and lupus nephri…
Lupus immune cells change how they use sugar for energy, a shift that drives the disease and kidney damage, opening doors to new metabolic t…
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
Could a New Drug Help Improve Kidney Function in Lupus Patients?
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal resp…
A new trial tests whether adding cenerimod to regular treatment can improve kidney function in adults with active lupus nephritis over 76 we…